Hainan Lecheng Medical and Drug Administration went to Yinfeng Biological Group for investigation
Release time:
2023-05-31
On May 31, in order to implement the "Hainan Provincial Xi Implementation Plan for the Theme Education of Socialism with Chinese Characteristics in the New Era of Xi Jinping" and the "Implementation Plan for Daxing Research among Party Organizations and Party Members and Cadres at All Levels in the Province", effectively solve the urgency and anxiety of the enterprise development process, and further promote the smart medical work in the Lecheng Pilot Zone, the Lecheng Medical and Drug Administration went to the Shandong Medical Association and Yinfeng Biological Group to carry out inspection and research work.
乐城医疗药品监管局局长范斌一行到山东医学会和银丰生物集团总部调研，座谈交流。
Zhang Lin, vice president of Shandong Medical Association, Rao Lin, deputy secretary general, Zhang Weizhong, deputy secretary general and director of the office, and Wang Baoqing, chairman of Yinfeng Biological Group, accompanied the discussion and exchange, at which Vice President Zhang Lin introduced the development of Shandong Medical Association and the recent work in clinical research, new technology introduction and international exchanges, and raised questions to the Lecheng Medical and Drug Administration on how to land the new hospital project in the Lecheng Pilot Zone, qualification declaration and handling, department construction acceptance, licensed drug and equipment use, medical technology and nursing training and other related issues.
Fan Bin, director of the Lecheng Medical and Drug Administration, introduced the latest policy of the Lecheng Pilot Zone, the new development idea of "sharing, specialty, and alliance" and the regulatory concept of "one center, two bottom lines, and three initiatives", and said that the survey was vigorously promoted by the Shandong Provincial Medical Association to introduce high-quality medical resources in Shandong Province into the Lecheng Pilot Zone, further enrich the medical resources of the Lecheng Pilot Zone, and bring benign development to talent training. Subsequently, Zeng Guangrong, a second-level researcher of Lecheng Medical and Drug Administration, answered the biggest difficulties faced by the development of the enterprise at this stage and other related questions, turning "passive approval" into "active service" to empower the development of the enterprise.
Through this exchange, we will accelerate the revitalization of Shandong's medical resources, introduce Shandong's high-quality medical resources into the Hainan Boao Lecheng Pilot Zone, and promote Shandong medical treatment to the world with the help of the policies of the Lecheng Pilot Zone, and jointly promote the treatment of refractory diseases in the two places.
This research and exchange gave clear guidance and put forward relevant suggestions for the work of the later hospital project, pointed out the direction for the next step of discipline construction and specialty landing, and believed that through the cooperation of all parties, the high-quality development process of medical industry in Shandong and Hainan will be further accelerated.
Subsequently, Wang Baoqing, chairman of Yinfeng Biological Group, accompanied the research group to visit the "Infinite Life Plan" science museum and the "Life Extension Plan" exhibition hall successively, and learned in detail about the storage and application prospects of cells in 5G scenarios, the application of cryogenic medicine, the first case of human cryopreservation in Asia, and the infinite possibilities of cryomedicine in organ transplantation and clinical application.
During this exchange and inspection, the research group successively learned about the industrial layout, cutting-edge technology, R&D and innovation, and achievement transformation of Yinfeng Biological Group in the field of biomedicine, and highly recognized and praised the achievements of Yinfeng Biological Group.
Yinfeng Biological Group is a high-tech enterprise specializing in technology research and development, medical transformation and clinical research in the biomedical field such as human cells, tissues and organ storage, gene sequencing technology, cell application technology, cryogenic medical technology and health management services. In the past 19 years, Yinfeng Biotech has taken the lead in opening up the health management service industry chain covering the whole life cycle of human beings in the country, with the development vision of "becoming a leading domestic and international first-class health management service provider for the whole life cycle of human beings", and contributing to the service of "Healthy China".
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
